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Abstract
Introduction Ductal carcinoma in situ (DCIS) of the breast
includes a heterogeneous group of preinvasive tumors with
uncertain evolution. Definition of the molecular factors
necessary for progression to invasive disease is crucial to
determining which lesions are likely to become invasive. To
obtain insight into the molecular basis of DCIS, we compared
the gene expression pattern of cells from the following samples:
non-neoplastic, pure DCIS, in situ component of lesions with
co-existing invasive ductal carcinoma, and invasive ductal
carcinoma.
Methods Forty-one samples were evaluated: four non-
neoplastic, five pure DCIS, 22 in situ component of lesions with
co-existing invasive ductal carcinoma, and 10 invasive ductal
carcinoma. Pure cell populations were isolated using laser
microdissection. Total RNA was purified, DNase treated, and
amplified using the T7-based method. Microarray analysis was
conducted using a customized cDNA platform. The concept of
molecular divergence was applied to classify the sample groups
using analysis of variance followed by Tukey's test.
Results Among the tumor sample groups, cells from pure DCIS
exhibited the most divergent molecular profile, consequently
identifying cells from in situ component of lesions with co-
existing invasive ductal carcinoma as very similar to cells from
invasive lesions. Additionally, we identified 147 genes that were
differentially expressed between pure DCIS and in situ
component of lesions with co-existing invasive ductal
carcinoma, which can discriminate samples representative of in
situ  component of lesions with co-existing invasive ductal
carcinoma from 60% of pure DCIS samples. A gene subset was
evaluated using quantitative RT-PCR, which confirmed
differential expression for 62.5% and 60.0% of them using initial
and partial independent sample groups, respectively. Among
these genes, LOX and SULF-1 exhibited features that identify
them as potential participants in the malignant process of DCIS.
Conclusions We identified new genes that are potentially
involved in the malignant transformation of DCIS, and our
findings strongly suggest that cells from the in situ component
of lesions with co-existing invasive ductal carcinoma exhibit
molecular alterations that enable them to invade the surrounding
tissue before morphological changes in the lesion become
apparent.
Introduction
Ductal carcinoma in situ (DCIS) of the breast is characterized
by a proliferation of malignant-appearing epithelial cells of the
ducts but without detachment of the basement membrane or
evidence of invasion [1]. This disease lies within a spectrum of
preinvasive lesions with a vast range of malignant potential.
DCIS can progress rapidly to invasive cancer or it may change
very slowly [2]. Therefore, an ability to identify which DCIS
ANOVA: analysis of variance; aRNA: amplified RNA; DCIS: ductal carcinoma in situ; DCIS-IDC: ductal carcinoma in situ with co-existing invasive 
ductal carcinoma; DEPC: diethylpyrocarbonate; dscDNA: double strand cDNA; HER: human epidermal growth factor receptor; IDC: invasive ductal 
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lesions are likely to progress to invasive carcinoma and over
what time interval would greatly enhance treatment selection
and outcome in breast cancer patients.
The current view of the malignant process is that cancer cells
acquire malignant potential by accumulating alterations that
permit them to overcome the strict rules of normal cell growth
regulation imposed by their environment [3]. Breast cancer is
a multistep process that manifests through a series of patho-
logical stages, namely atypical ductal hyperplasia, DCIS and
invasive ductal carcinoma (IDC), the latter being potentially
lethal if subsequent development of distant metastasis occurs
[4]. Molecular and pathological evidence suggests that DCIS
can be precursor to invasive disease (although this is not with-
out exception) [5-11]. However, it is not clear which cell pop-
ulations progress to invasive disease and what molecular
properties give them the capacity to spread to surrounding
tissue.
Despite much research effort, the molecular basis of breast
cancer tumorigenesis and progression [9,12-17] has not com-
pletely been elucidated. Two major approaches have been
used to address these issues: oligo/cDNA microarrays and
laser microdissection. Microarrays allow researchers to exam-
ine the expression of several genes simultaneously, identifying
gene sets that discriminate groups of cancer samples with
common clinical or pathological characteristics and risk for
progression to IDC. Laser microdissection is crucial in permit-
ting the molecular analysis of defined, homogenous cell types
from a specific solid tissue. Both methodologies have been
used to discover novel prognostic markers and to predict dis-
ease outcomes [9,16,18,19].
The pathological classification of DCIS does not accurately
predict invasive disease. In the present study we compared
the gene expression profiles of cells captured from in situ
component lesions, pure DCIS, and in situ component of
DCIS with co-existing IDC (DCIS-IDC), with the goal being to
find molecular makers that can predict risk for invasive dis-
ease. We also examined epithelial cells of initial (non-neoplas-
tic epithelial cells) and later stages (IDC cells) of ductal
carcinoma progression.
The molecular characteristics of cells from the in situ compo-
nent of DCIS-IDC are more similar to cells from IDC than to
those from pure DCIS (the latter being morphologically identi-
cal), which strongly suggests that their molecular reprogram-
ming precedes morphological alteration in the lesion.
Moreover, we identified several candidate genes, including
LOX  [GenBank: NM_002317] and SULF-1  [GenBank:
NM_001128206], which are putatively involved in the acquisi-
tion of the capacity to invade adjacent tissues of DCIS. These
genes may serve as molecular markers that can identify those
DCIS lesions that may become invasive.
Materials and methods
Samples
Fresh-frozen human breast tumor samples were retrieved from
the Tumor Tissue Biobank of the Medical and Research
Center – Hospital A C Camargo, São Paulo. Sections 5 μm
thick from the fresh-frozen tumor blocks were cut onto glass
slides, stained with hematoxylin and eosin, and reviewed by a
pathologist. The hematoxylin and eosin stained sections were
used to evaluate and select appropriate tumor areas corre-
sponding to each histological component. The histological
grade of the DCIS was assigned in accordance with the
World Health Organization scale [20], and IDC was classified
in accordance with the Scarff-Bloom-Richardson grading
scheme [21,22]. Forty-one samples were evaluated, consist-
ing of four non-neoplastic breast samples, five pure DCIS
(stage 0) samples, 11 in situ component of DCIS-IDC sam-
ples, and 10 IDC samples; these served as initial sample sets.
An additional 11 in situ component of DCIS-IDC samples
were evaluated as an independent sample set. The non-neo-
plastic samples were obtained from perilesional mammary
specimens from patients obtained during resection of benign
lesions. A pathologist subjected all slides representative of
pure DCIS to a careful histopathological analysis in order to
ensure the absence of any previously undetected microinva-
sions. At least 5 years of follow-up data were available for all
patients.
The patients had a mean age of 49 years, and none of them
had received preoperative systemic treatment. The patients'
clinical characteristics are summarized in Table 1. The expres-
sion patterns of estrogen receptor, progesterone receptor,
and human epidermal growth factor receptor (HER)2/neu
were positive in the majority of the samples. The research was
approved by the Ethics Committee of the Medical and
Research Center – Hospital A C Camargo, under protocol
number 587/04. All participants gave written, informed
consent.
Laser capture microdissection
Cells were laser captured using the PixCell II LCM system
(Arcturus Engineering, Mountain View, CA, USA). About
4,000 cells were captured from 4 to 7 μm frozen sections,
mounted onto glass slides, and stained with 100 μl of nuclear
fast red (C.I.60760; Certistain®; Merck, Darmstadt, Germany)
for microscopy. Only one type of cells was isolated from each
sample group. Non-neoplastic breast epithelium samples
were epithelial cells without contamination with stromal cells;
pure DCIS samples were tumor cells captured from ducts of
pure DCIS lesion; in situ component of DCIS-IDC samples
were tumor cells captured from in situ component of the
DCIS-IDC lesion; and IDC samples were infiltrative tumor cells
captured from the invasive lesion.Available online http://breast-cancer-research.com/content/10/5/R87
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Table 1
Patient and tumor characteristics
Specimen description Stage Age (years) TNM Nuclear grade ER PR p53 status HER2/neu
Initial sample
43 DCIS (pure) 0 37 T3N0M0 ND - - + ND
44 DCIS (pure) 0 44 ToN0M0 2 and 3 + + - +
46 DCIS (pure) 0 43 T2N0M0 3 + + - + (3+)
48 DCIS (pure) 0 52 T2N0M0 3 + + - + (3+)
49 DCIS (pure) 0 58 TicN0M0 3 (High grade) - - - + (3+)
2 DCIS IIa 48 T2N0M0 3 + + + +
13 DCIS IIa 75 T2N0M0 2 + + + + (2+)
25 DCIS IIa 34 T2N0M0 3 + + + + (3+)
33 DCIS I 38 T1cN0M0 3 + - - -
45 DCIS I 55 T1N0M0 3 - - + + (3+)
66 DCIS IIIb 44 T4bN1M0 3 + + + - (1+)
69 DCIS IIb/IIIa 57 T2N1M0/pT2N2M0 2 + + ND + (2+)
75 DCIS IIb 43 pT2N0M0 IDC 2/DCIS 3 - - + + (3+)
85 DCIS I 73 T1cN0M0 pT3N0M0 2 + + - + (2+)
86 DCIS ND 46 T2N1M0 3 + + + + (2+)
87 DCIS IIa 48 T2N1M0 3 - - - + (2+)
1 IDC IIa 45 T2N0M0 2 - - - + (3+)
3 IDC IIa 43 T1cN0M0 3 + - - + (3+)
24 IDC IIa 54 T2N0M0 3 + + + + (3+)
50 IDC III b 71 T4N2M0 3 + + + + (2+)
51 IDC II a 43 initial T2N0M0 3 - ND ND + (3+)
53 IDC III a 43 T2N2M0 3 + + ND + (2+)
56 IDC I ND ND ND ND ND ND ND
80 IDC IIa 44 pT1cpN1M0 3 + + - -
81 IDC IIb 31 T2N1M0 3 - - + + (3+)
83 IDC IIa 48 T2N0M0 2 + + - + (2+)
Independent group of DCIS/IDC samples
1 DCIS ND 58 T1N0M0 3 + + + + (2+)
2 DCIS ND 40 T1N1M0 3 + + - + (2+)
3 DCIS ND 27 T1N0M0 1 (Low grade) ND ND ND ND
4 DCIS ND 53 ND 3 (High grade) + + + + (2+)
5 DCIS ND 51 T1N0M0 2 + + ND + (2+)
6 DCIS III a 54 T3N1M0 3 (High grade) - - ND ND
8 DCIS ND 52 T2N1M0 3 - - + + (3+)
9 DCIS ND 38 T1N1M0 3 (High grade) - - + - (1+)
3 DCIS ND 39 T2N0M0 ND + + + -
8 DCIS ND 49 T2N0M0 ND + + ND -Breast Cancer Research    Vol 10 No 5    Castro et al.
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A representative sample of cells from the pure DCIS depicting
the different phases during the microdissection procedure is
shown in Figure 1.
RNA isolation and amplification
Laser capture microdissection (LCM) captured cells on Cap-
Sure™ HS LCM Caps (Arcturus Engineering) were resus-
pended in 10 μl of PicoPure RNA extraction buffer (Arcturus
Engineering). Total RNA was extracted by using the PicoP-
ure™ RNA Isolation kit (Arcturus Engineering #KT0204) and
DNase treated using the RNase-Free DNase Set (Qiagen
#79254; Qiagen-Germantown MD USA), in accordance with
the manufacturer's instructions. A two-round linear amplifica-
tion procedure, based on T7-driven amplification, was per-
formed following a previously described protocol [23] with
some modifications described below. The total RNA was first
denatured at 70°C for 10 minutes in presence of 200 ng oligo
(dT) [24]-T7 primer (5'-AAA CGA CGG CCA GTG AAT TGT
AAT ACG ACT CAC TAT AGG CGC T (24)-3'; 57 base pairs)
and snap cooled on ice.
Reverse transcription was performed by adding 1× first strand
buffer and 0.01 mol/l dithiothrectol (Invitrogen Life Technol-
ogy, Carlsbad, CA, USA), 2 μl diethylpyrocarbonate (DEPC;
Sigma, St Louis, MO, USA) treated water, 40 U rRNasin
(Promega, Madison, WI, USA), 1 mmol/l dNTP (Amersham
Biosciences, Piscataway, NJ, USA), and 400 U SuperScript™
II Reverse Transcriptase (Invitrogen Life Technology) to a final
volume of 20 μl. The reaction was incubated for 120 minutes
at 42°C. Second-strand synthesis was performed by adding
53 μl of DEPC-treated water, 20 μl of 5× second strand buffer
(Invitrogen Life Technology), 1 mmol/l dNTP, 1 U RNase H
(Invitrogen Life Technology), 10 U Escherichia coli DNA
ligase, and 40 U E. coli DNA polymerase I (Invitrogen Life
Technology) to a final volume of 100 μl. The reaction was incu-
bated for 2 hours at 16°C. Ten units of T4 DNA polymerase I
(Invitrogen Life Technology) were added and incubated again
at 16°C for 5 minutes.
The double strand cDNA (dscDNA) was stopped by adding
0.05 mol/l EDTA. UltraPure™ Phenol (Invitrogen, Carlsbad,
CA, USA):chloroform:isoamyl alcohol (Merck), at a ratio of
25:24:1 and a pH of 8.0, was used for cDNA purification. The
dscDNA was precipitated with absolute ETOH (Merck) and
resuspended in 10 μl DEPC-treated water. The dscDNAs
were subjected to in vitro transcription using reagents from
Ribomax™ Large scale RNA production system T7 kit
(Promega), in accordance with the manufacturer's recommen-
dation. The amplified RNA (aRNA) was reverse transcribed
into cDNA using 9 μg random hexamer (dN6; Amersham Bio-
sciences, Little Chalfont, UK). cDNA synthesis was continued
with the same conditions used in the first strand of the first
round. The second strand was synthesized using Advantage®
cDNA Polymerase (Clontech, Mountain View, CA, USA), and
purification was performed in accordance with the methodol-
ogy cited above.
The aRNA quality, in terms of purity and integrity, was
assessed by absorbance at 260/280 nm using a GeneQuant
pro spectrophotometer (Amersham Pharmacia Biotech, Little
Chalfont, UK) and by electrophoresis in 1% UltraPure™ Agar-
ose (Invitrogen Life Technology) gel with ethidium bromide
staining (Sigma, St Louis, MO, USA), respectively. Only aRNA
15 DCIS II b 69 T2N1M0 ND + + ND + (2+)
Unless otherwise stated, 'DCIS' means in situ component of DCIS-IDC. DCIS, ductal carcinoma in situ; DCIS-IDC, ductal carcinoma in situ with 
co-existing invasive ductal carcinoma; ER, estrogen receptor; IDC, invasive ductal carcinoma; ND, not determined; PR, progesterone receptor; 
TNM, tumor size, nodal status and metastasis.
Table 1 (Continued)
Patient and tumor characteristics
Figure 1
Breast epithelium captured from DCIS by LCM Breast epithelium captured from DCIS by LCM. Images of (a) pre-capture and (b) postcapture tissues, and (c) captured epithelial tumor cells. DCIS, 
ductal carcinoma in situ; LCM, laser capture microdissection.Available online http://breast-cancer-research.com/content/10/5/R87
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samples yielding a minimum of 15 μg and presenting a smear
concentration between 300 and 700 base pairs (which guar-
antees high quality hybridization) were further processed.
Total RNA from HB4a normal luminal epithelial mammary cells
[24] was extracted and amplified following the same protocol
and used as a reference for microarray hybridizations.
cDNA microarrays and probes
We used a customized cDNA platform (4.8K002 platform)
comprising 4,608 cDNAs that represent human genes [25].
The labeled cDNA was generated in a reverse transcriptase
reaction in the presence of 4 μg aRNA, 9 μg random hexamer
primer (Invitrogen Life Technology), Cy3-labeled or Cy5-
labeled dCTP (Amersham Biosciences, Little Chalfont, UK),
and 400 U SuperScript II (Invitrogen Life Technology). The
residual dye was removed using illustra AutoSeq™ G-50 (GE
Healthcare, Little Chalfont, UK). Equal amounts of test and ref-
erence cDNA reverse colored Cy-labeled product were com-
petitively hybridized against the cDNA probes in microarray
slides. Dye swap was performed for each sample analyzed
and used as replicate samples. Pre-hybridization was carried
out in a humidified chamber at 42°C for 16 to 20 hours, and
hybridizations were performed on GeneTac Hybridization Sta-
tion (Genome Solutions, Ann Arbor, MI, USA) at 42°C.
Intensity signal capture and analysis
After hybridization, slides were washed as follows: 2× Saline-
Sodium Citrate (SSC) for 10 minutes, 0.1 × SSC/0.1% SDS
for 10 minutes (two times), and 0.1 × SSC for 10 minutes (two
times) at 37°C. All solutions were pre-heated to 42°C. Hybrid-
ized arrays were scanned on the ScanArray™ Express (Pack-
ard BioScience Biochip Technologies, Billerica, MA, USA),
and Cy5/Cy3 signals were quantified using the histogram
method with ScanArray Express software (Perkin-Elmer Life
Sciences, Boston, MA, USA). Fluorescent intensities of Cy5
and Cy3 channels on each slide were subjected to spot filter-
ing and normalization. We first eliminated all saturated points
(≥ 63,000; approximately 16 bits) and performed a local back-
ground subtraction, considering for analysis only those spots
with positives values. Normalization was performed using
locally weighted linear regression within and across arrays for
inter-slide normalization. Local normalization has the advan-
tage that it can help to correct for systematic spatial variations
in the array [26]. After normalization, data for each gene were
reported as the logarithm of the expression ratio used to rep-
resent the relative gene expression levels in the experimental
samples. The raw data from hybridizations and experimental
conditions can be obtained at the Gene Expression Omnibus
[27] under accession number GSE11042. A detailed descrip-
tion of the platform array is available in accession number
GPL1930.
Statistical analysis
For applying the concept for molecular divergence and to
identify the most distinct group of samples, the general expres-
sion patterns were compared between the sample groups
(non-neoplastic, pure DCIS, in situ component of DCIS-IDC,
and IDC) using the analysis of variance (ANOVA) statistical
test (positive false discovery rate – pFDR < 0.01) [28] fol-
lowed by Tukey's test [29]. To select the putative genes
involved in DCIS progression, two-by-two comparisons
among non-neoplastic, pure DCIS, and in situ component of
DCIS-IDC sample groups were performed; differentially
expressed genes, whose expression levels exhibited at least
twofold change, were selected. Downregulated and upregu-
lated genes were analyzed separately. A Venn diagram was
constructed to select the genes of interest.
To determine decay rate statistics for collections of genes
belonging to the different gene sets, automated analysis of
gene function was required. The functional assignments of the
genes were obtained using the χ2 distribution of Onto-Tools
(developed by Intelligent Systems and Bioinformatics Labora-
tory from Department of Computational Sciences of Wayne
State University) [30]. Functional processes were considered
as significant if the P value was under 0.01. Functional assess-
ments, which were represented by only one gene in the plat-
form, were not taken into consideration in order to avoid
artifactual results.
For clustering samples based on gene expression profiles, we
applied a nonsupervised hierarchical clustering based on
Euclidean distance and average linkage. The reliability of the
clustering was assessed by the Bootstrap technique using
MEV (MultiExperiment Viewer – Boston, MA, USA) [31].
Quantitative RT-PCR
Quantitative RT-PCR reactions were performed using the ABI
Prism™ 7700 Sequence Detection System (Applied Biosys-
tems, Foster City, CA, USA). Aliquots of cDNA from aRNA
were used as templates. RT-PCR reactions were carried out
using SYBR® Green PCR MasterMix (Applied Biosystems) in
a total volume of 20 μl using the following program: 2 minutes
at 50°C and 10 minutes at 95°C for the initial denaturing, fol-
lowed by 40 cycles at 95°C for 15 seconds and 60°C for 1
minute. The list of oligonucleotide sequences is shown in
Table 2. Finally, dissociation curves were generated at 95°C
for 15 seconds, 60°C for 30 seconds, and 95°C for 15 sec-
onds. To evaluate the amplification of nonspecific products
and primer-dimer formation, dissociation curves were analyzed
and aliquots of each reaction were subjected to silver staining
acrylamide gel electrophoresis. The efficiency of each pair of
primers was calculated using standard curve dilutions (as
described in the Applied Biosystems protocols). The analysis
was conducted using the cDNA converted from the aRNA
used in the microarray study. The reactions were performed in
duplicate. Three internal control genes, namely HPRT1 [Gen-
Bank:NM_000194] [32], GAPDH [GenBank:AJ005371], and
BCR  [GenBank:NM_004327], were considered in gene
expression normalization. Relative gene expression betweenBreast Cancer Research    Vol 10 No 5    Castro et al.
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sample groups was calculated using the Pfaffl model [33],
employing the efficiency-corrected equation.
Results
Laser microdissection, RNA extraction, and microarray 
experiments
To generate a precise correlation between specific epithelial
cells and their gene expression patterns, we integrated the use
of LCM and T7-based RNA amplification with cDNA microar-
rays. This procedure permitted gene expression profile analy-
sis with a cell based, rather than tissue based, resolution. To
characterize the molecular alterations of cells from the in situ
component of the two breast cancer lesions, namely DCIS and
DCIS-IDC, we analyzed the gene expression profiles of both.
We also used non-neoplastic epithelial cells and cells from
IDC lesions as examples of zero and complete progression,
respectively.
The Pearson correlation average between all hybridization rep-
licates used in this study was 0.91. All replicates clustered
together in dendrograms reporting suitable correction of the
individual dye incorporation efficiency by normalization proce-
dure and high experimental reproducibility.
Molecular divergence concepts based on general cell-
based gene expression profile
To classify the groups of samples according to their molecular
divergence, we used the number of differentially expressed
genes as our distance measure; the larger the number of dif-
ferentially expressed genes between one sample type and all
the others, the more distant the sample was allocated and con-
sequently more molecularly divergent. To accomplish this, an
ANOVA test corrected by pFDR (<0.01) was performed on
the four sample groups, identifying 764 differentially
expressed genes (see Additional file 1). Next, Tukey's test was
performed through two by two comparisons between the dis-
tinct groups. As expected, the non-neoplastic epithelial breast
cells exhibited the most divergent expression profile (29%). A
total of 221 genes out of 764 were only differentially
expressed between non-neoplastic and the three tumor cell
groups. In contrast, for cells from pure DCIS, the in situ com-
ponent of DCIS-IDC and IDC, when compared with all of the
other three, there were 12 (1.6%), 37 (4.8%) and 6 (0.3%) dif-
ferentially expressed genes out of 764, respectively.
Using the same metrics, a new round of analysis was per-
formed excluding the non-neoplastic sample group in order to
Table 2
List of the oligonucleotides sequences used for quantitative real-time PCR
Gene symbol Annotation Primer sequences
Target genes CGI-41 CGI-41 protein Forward: CCAGGCGTGCAGGGTATC
Reverse: GCCCCCGCTGCACAT
C16orf5 Chromosome 16 open reading frame 5 Forward: CAGCCAGAGCAGTTAGCCAGTTA
Reverse: CTGACTCCAGACAACTTACCCATTC
GOSR2 Golgi SNAP receptor complex member 2 Forward:GCAGGAGAGACAGCGAGAAGA
Reverse:TGCAGTGATTCGTCCATTGG
MARK3 MAP/microtubule affinity-regulating kinase 3 Forward: AGACACTCAGTGATTCAGAATGGC
Reverse: GAAGCAACTGGAGTTCTCTGATCA
LOX Lysyl oxidase Forward: CAGGACATCATGCGTATGCC
Reverse: CCAGGCACTGATTTATCCATTG
STK25 Serine/threonine kinase 25 (STE20 homolog, yeast) Forward: ACCTGGTGGAGCGAGTGC
Reverse: TTCAGCGGGTGGATGTCAG
SULF-1 Sulfatase 1 Forward:GGCATTTTGAATCAGCTACACGTA
Reverse:TCCCATCCATCCCATAACTGTC
TXNL2 Thioredoxin-like 2 Forward: GACCACAGGCGTGCACC
Reverse: GATACCTTTCCTCATCCATCACAAG
Endogenous genes HPRT hypoxanthine phosphoribosyltransferase 1 Forward: GAACGTCTTGCTCGAGATGTGA
Reverse: TCCAGCAGGTCAGCAAAGAAT
GAPDH Glyceraldehyde 3-phosphate dehydrogenase Forward: ACCCACTCCTCCACCTTTGA
Reverse: CTGTTGCTGTAGCCAAATTCGT
BCR Breakpoint cluster region Forward: CCTTCGACGTCAATAACAAGGAT
Reverse: CCTGCGATGGCGTTCACAvailable online http://breast-cancer-research.com/content/10/5/R87
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identify which tumor cell population exhibits the highest molec-
ular divergence level among the three analyzed groups. The
ANOVA corrected by pFDR (<0.01) identified 90 variable
genes among the three groups of neoplastic cells (see Addi-
tional file 2). Tukey's test revealed that cells from pure DCIS
exhibited the most distinct gene expression profile, with 75
genes (83%) out of 90 being differentially expressed in com-
parison with the other two groups of tumor cells. For cells from
the in situ component of DCIS-IDC and cells from IDC lesions,
16 genes (18%) and 6 genes (7%) out of 90 were found to be
differentially expressed, respectively (Figure 2). A parallel anal-
ysis between molecular and morphological aspects yielded
contradictory results, because – in terms of morphological fea-
tures – IDC had the most distinct features and pure DCIS and
the in situ component of DCIS-IDC lesions exhibited identical
patterns. On the other hand, in terms of molecular features,
cells from pure DCIS exhibited the most distinct molecular
expression profile, and consequently cells from in situ compo-
nent of DCIS-IDC retains high similarity to cells from IDC,
which suggests alterations in gene expression programs of
cells from in situ component of DCIS-IDC before their pro-
gression to IDC.
Selection of putative genes involved in ductal carcinoma 
progression
DCIS progresses to malignant disease when some of the
tumor cells acquire invasive capacity. Our previous data
strongly suggested that the in situ component of DCIS-IDC
already harbors molecular alterations that signal establishment
of the invasive process. Based on these findings, we reasoned
that the genes potentially involved in the earliest molecular
step in acquiring the capacity to invade the surrounding tissue
might be among the genes that are differentially expressed
between cells from in situ component of DCIS-IDC and both
pure DCIS and non-neoplastic groups.
To identify these genes we conducted an ANOVA test cor-
rected by pFDR (<0.01) among non-neoplastic, pure DCIS,
and the in situ component of DCIS-IDC, identifying 785
altered genes (see Additional file 3). The two-by-two compari-
sons between samples from the three groups revealed 8, 215,
and 161 genes between non-neoplastic versus pure DCIS,
non-neoplastic versus in situ component of DCIS-IDC, and
pure DCIS versus the in situ component of DCIS-IDC, respec-
tively (Figure 3a; see Additional file 4). To eliminate genes
involved in tumor formation from those potentially involved in
tumor progression, we subtracted eight genes that were differ-
entially expressed between cells from non-neoplastic and pure
DCIS cells (Figure 3a). The common differentially expressed
genes between in situ component of DCIS-IDC versus non-
neoplastic or pure DCIS were selected in order to choose the
more robust genes, yielding 147 genes classified as poten-
tially implicated in DCIS progression. From those, 126 were
upregulated and 21 were downregulated in pure DCIS (see
Additional file 5), suggesting that the malignant process of
tumor cells from pure DCIS to in situ component of DCIS/IDC
occurs rather by downregulation than by upregulation of gene
expression.
Functional annotation of this gene set, according to the Onto-
Tools database, revealed a statistically significant enrichment
of genes involved in cell adhesion (represented by C20orf42
[GenBank:AL118505],  LPXN  [GenBank:NM_004811],
Figure 2
Comparison among the gene expression profile and morphological characteristics of progression of breast ductal carcinoma Comparison among the gene expression profile and morphological characteristics of progression of breast ductal carcinoma. (a) Non-neoplastic tis-
sue (20×). (b) Pure DCIS (10×). (c) DCIS-IDC (arrow; hand lens). (d) IDC (hand lens). DCIS, ductal carcinoma in situ; DCIS-IDC, ductal carcinoma 
in situ with co-existing invasive ductal carcinoma; IDC, invasive ductal carcinoma.Breast Cancer Research    Vol 10 No 5    Castro et al.
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Figure 3
Putative genes involved in ductal carcinoma progression Putative genes involved in ductal carcinoma progression. (a) Venn diagram depicting the common and distinct genes in each comparison (downreg-
ulated and upregulated genes were analyzed separately). (b) Dendogram based on the expression profile of the 147 gene set. Green circles indi-
cate non-neoplastic samples; yellow indicates pure DCIS, and red indicates in situ component of DCIS-IDC samples. (c) Legend of cluster support. 
(d) Scaled down representation of the entire cluster shown in panel b. Each row represents a single gene and each column a sample. Red indicates 
upregulation, green indicates downregulation, and black indicates no change in expression level compared with the reference sample. Gray indi-
cates that no intensity was detected. DCIS, ductal carcinoma in situ; DCIS-IDC, ductal carcinoma in situ with co-existing invasive ductal carcinoma.Available online http://breast-cancer-research.com/content/10/5/R87
Page 9 of 14
(page number not for citation purposes)
PCLKC  [GenBank:NM_017675],  DGCR2  [Gen-
Bank:NM_005137],  AZGP1  [GenBank:NM_001185],
CHST10  [GenBank:NM_004854],  ITGB2  [Gen-
Bank:NM_000211],  PLEKHC1  [GenBank:AK291738],
PCDH10  [GenBank:NM_032961], and NEDD9  [Gen-
Bank:NM_006403]) and cellular defense (represented by
CXCL9  [GenBank:NM_002416],  MAPRE2  [Gen-
Bank:NM_014268], and C3AR1  [GenBank:NM_004054]).
LPXN  [GenBank:NM_004811] and NEDD9  [Gen-
Bank:NM_006403] have been reported as being involved in
cancer progression. Over-expression of LPXN  [Gen-
Bank:NM_004811] and NEDD9  [GenBank:NM_006403]
resulted in increased migration in the bone-derived metastatic
prostate cancer cell line [34] and in promotion of metastatic
melanoma [35], respectively. These reports support our data,
which reveal high expression of these genes in the in situ com-
ponent of DCIS-IDC compared with pure DCIS cells. The 147
genes were organized into seven different biological classes in
a hierarchical manner (Table 3).
The hierarchical clustering based on the expression pattern of
this gene set resulted in two main branches with high level of
reliability (Figure 3b,c). Non-neoplastic samples and 60% of
the pure DCIS samples were discriminated from 100% of the
in situ component of DCIS-IDC samples (Figure 3b). The abil-
ity of this gene set to generate an expression pattern (Figure
3d) that segregated the two groups of cells (pure DICS and in
situ  component of DCIS-IDC) relatively well, grouping
together the samples representing cells from non-neoplastic
and cells from pure DCIS lesion, strengthened the hypothesis
that those genes might be involved in the early molecular alter-
ations that are necessary for launching of the invasive process.
Confirmation of differential expression between pure 
DCIS and DCIS-IDC by quantitative RT-PCR
In order to evaluate the robustness of our microarray findings
and to avoid choosing false differentially expressed genes
because of technical limitations, we randomly selected eight
genes from the 147 gene set (Table 4) and performed quanti-
tative RT-PCR in duplicate experiments. The average of the
internal control genes (HPRT1  [GenBank:NM_000194],
GAPDH  [GenBank: AJ005371] and BCR  [Gen-
Bank:NM_004327]) was used in a normalization procedure.
Using the initial sample sets and the criteria of ≥ 2-fold change,
five out of eight genes (62.5%) exhibited agreement in both
methodologies. The genes C16orf5 [GenBank:NM_013339],
GOSR2  [GenBank:NM_004287], and TXNL2 [Gen-
Bank:AL138831] were upregulated, and LOX  [Gen-
Bank:NM_002317] and SULF-1
[GenBank:NM_001128206] were downregulated in pure
Table 3
Genes potentially implicated in DCIS progression functionally classified within the biological process category
Functional process Downregulated genes in pure DCIS Upregulated genes in pure DCIS
Cell adhesion and migration - AZGP1, C20orf23, C20orf42, CHST10, COL17A1, DGCR2, 
GPR98, ITGB2, KIF1A, LPXN, NEDD9, PCDH10, PCLKC, 
PLEKHC1, RGMB
Signal transduction CORO1C, CXCL9, IGSF6, LOX, NCOA4, 
NMU, SKIL
ARHGAP19, ARHGAP9, C16orf5, C3AR1, CHRNB1, 
EPOR, FCGR2B, FCN1, FGFBP1, GIPC1, GPR77, KDR, 
MAPRE2, PIAS2, RHOU, STK25
Cell proliferation and apoptosis NOX4, SULF1 ANAPC13, CDC45L, ERC1, IFT57, RARRES3, REC8L1, 
SHC1, UTP20
Transcriptional regulation MED10, PHTF1 AOF2, ATF2, ETNK2, IRF8, MBD3, MGC21874, SMARCA3, 
SOX13, TARDBP, ZBTB5
Metabolism P4HA1 B4GALT5, BCHE, CA3, CPNE3, CPT1A, DHRS12, FN3K, 
GBGT1, OSBPL7, PEPD, PITPNM2, UFD1L, ZFP36L1
Miscellaneous CCT5, MARCH8, PTBP2, RAD51AP1 ALMS1, ARFIP1, BOP1, CAMP, CAV1, CIRBP, CLINT1, 
CLTCL1, CTSZ, DHX35, EYA2, FCGR3A, GOSR2, IMMT, 
INOC1, KBTBD10, KCTD15, KIAA0664, KPNA6, LSM4, 
MARK3, MRPS17, NGDN, NUP50, P4HB, PMPCA, POLD3, 
POMGNT1, PPP2R3A, RABEPK, RPL3, RPL41, RSL1D1, 
SAMD4A, SLC6A20, SLC9A5, SPOCK2, STX11, SV2B, 
SYN1, TBC1D9B, TRAP1, TXNDC11, TXNL2, UBXD1, 
VPS54
Unknown C13orf23, C7orf24, HN1, KIAA1211, 
RUNDC1
ADFP, ANKRD6, BIN2, C10orf26, C13orf24, C1orf66, 
CTTNBP2NL, DENND3, FAM40B, ITPKC, KIAA0748, 
LETMD1, LRCH2, LTBP3, NCDN, PPM1H, PPTC7, RNF43
Genes belonged to more than one biological process were assigned in a hierarchical manner in the following order: cell adhesion and migration; 
signal transduction; cell proliferation and apoptosis; transcriptional regulation; and metabolism. Those with no classification in the five categories 
were classified as miscellaneous. DCIS, ductal carcinoma in situ.Breast Cancer Research    Vol 10 No 5    Castro et al.
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DCIS in comparison with in situ component of DCIS-IDC.
These five genes were also evaluated in an independent group
of 11 in situ component of DCIS-IDC samples (Table 5). Three
genes (60%; GOSR2 [GenBank:NM_004287], LOX [Gen-
Bank:NM_002317], and SULF-1  [Gen-
Bank:NM_001128206]) exhibited agreement with the
previous data, strengthening the hypothesis that these genes
are involved in the malignant process of DCIS.
Because we were interested in identifying genes that are
involved with the acquisition of invasive capacity in DCIS, we
reasoned that these genes should not exhibit differential
expression between cells from non-neoplastic cells and pure
DCIS cells, as neither of these cell types has established inva-
sion capacity. Likewise, we would expect there to be no differ-
ence in expression level between cells from the in situ
component of DCIS-IDC and IDC lesions, in which – despite
of the morphological differences in the tissue – the capacity
and program of invasion are already established. Therefore,
the five genes confirmed in the initial sample set were evalu-
ated in non-neoplastic and IDC samples. Based on our selec-
tion criteria, three genes (C16orf5 [GenBank:NM_013339],
LOX  [GenBank:NM_002317], and SULF-1  [Gen-
Bank:NM_001128206]) showed the expected gene expres-
sion behavior in the four sample groups, exhibiting slight or no
difference between the group with no invasive program (non-
neoplastic and pure DCIS) and that in which the invasive pro-
gram is already established (DCIS-IDC and IDC; Figure 4a).
The expression levels of these three genes exhibited statisti-
cally significant differences between the cells lacking the inva-
sive program (non-neoplastic and pure DCIS) and cells
possessing the invasive program (in situ component of DCIS-
IDC and IDC; Figure 4b). This strongly indicates that LOX
[GenBank:NM_002317] and SULF1  [Gen-
Bank:NM_001128206], confirmed in the initial and independ-
Table 4
Genes selected for quantitative RT-PCR experiments
Gene symbol Microarray (fold change) Quantitative RT-PCR (fold change)
Target genes CGI-41 5.3 1.9
C16orf5 5.5 2.6a
GOSR2 4.0 2.9a
MARK3 4.9 -1.4
LOX -2.0 -11.6a
STK25 2.0 -1.5
SULF-1 -4.0 -11.9a
TXNL2 4.2 3.0a
Positive and negative numbers indicate upregulated and downregulated genes in pure DCIS, respectively. aGenes confirmed using both 
methodologies. DCIS, ductal carcinoma in situ.
Table 5
Genes selected for quantitative RT-PCR experiments using an independent sample set of in situ component of DCIS/IDC (11 
samples)
Gene symbol Microarray (fold change) Quantitative RT-PCR (fold change)
Target genes C16orf5 5.5 1.4
GOSR2 4.0 6.4a
LOX -2.0 -3.6a
SULF-1 -4.0 -37a
TXNL2 4.2 -13.4
Positive and negative numbers indicate upregulated and downregulated genes in pure DCIS, respectively. aGenes confirmed using both 
methodologies. DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma.Available online http://breast-cancer-research.com/content/10/5/R87
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ent group of in situ component of DCIS-IDC samples, are
potentially involved in the acquisition of invasive capacity in
DCIS.
Discussion
Characterization of the molecular events that are associated
with DCIS progression has been among the major aims of the
scientific community. Even though great efforts to decipher
the molecular basis of DCIS have been made
[2,9,13,14,16,36-38], these molecular events remain poorly
understood. Studies have been limited by the low availability of
pure DCIS frozen samples. In this study, we combined the use
of LCM, RNA amplification, and microarray technology to char-
acterize the gene expression pattern of cells captured from
pure DCIS and in situ component of DCIS-IDC, which retain
identical morphological characteristics in the tissue. Non-neo-
plastic epithelial cells and IDC lesion cells were also analyzed.
The gene expression profile analysis of cells from three types
of breast cancer lesions (pure DCIS, in situ component of
DCIS-IDC, and IDC) yielded surprising results. We found that,
rather than cells from IDC, cells from pure DCIS had the most
divergent molecular aspects, which is in contrast to the mor-
phological features. This finding is directly and indirectly sup-
ported by recent reports. Recent studies relating the
expression of Her-2/neu, steroid receptors (estrogen receptor
and progesterone receptor), Ki67, p53, and epidermal growth
factor receptor in pure DCIS to in situ component of DCIS-
IDC have suggested that both components have distinct
molecular characteristics [39-42]. Gene expression analyses
of the two distinct morphological components, the in situ com-
ponent of DCIS-IDC and IDC, using matched and non-
matched samples have identified very similar molecular pro-
files [2,9,16,38]. Based on these findings, we speculate that
either the acquisition of invasive capacity of the DCIS cells is
driven by a very small number of genes that play a key role in
the invasion process, or the molecular alteration occurs before
the morphological modification of the lesion. The findings pre-
sented here support the latter hypothesis, strongly suggesting
that the molecular alteration of cells from in situ component of
DCIS-IDC is already established before the lesion exhibits
morphological changes.
In practical terms, one of the major contributions of our study
lies in using the molecular divergences between in situ com-
ponents of the two types of lesions, which have identical mor-
phological characteristics but distinct malignant potential, to
identify gene markers that may predict the risk for progression
from pure DCIS to invasive disease.
We validated five genes by quantitative RT-PCR in the initial
sample sets, which showed 62.5% of agreement in both meth-
Figure 4
Gene expression behavior among samples that mimic breast cancer progression Gene expression behavior among samples that mimic breast cancer progression. (a) Gene expression difference between identical morphologic 
samples (pure DCIS and in situ component of DCIS-IDC) by analysis of variance. (b) Comparison between two groups (non-neoplastic [N] + pure 
DCIS and in situ component of DCIS-IDC + IDC] by quantitative RT-PCR. DCIS, ductal carcinoma in situ; DCIS-IDC, ductal carcinoma in situ with 
co-existing invasive ductal carcinoma.Breast Cancer Research    Vol 10 No 5    Castro et al.
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odologies and ensured that our microarray data were robust.
The  GOSR2  [GenBank:NM_004287],  C16orf5  [Gen-
Bank:NM_013339], and TXNL2  [GenBank:AL138831]
genes were over-expressed in pure DCIS when compared
with the in situ component of DCIS-IDC. The GOSR2 [Gen-
Bank:NM_004287] finding was also confirmed in an inde-
pendent group of 11 in situ component DCIS-IDC samples.
The GOSR2 [GenBank:NM_004287] gene encodes a mem-
brane trafficking protein, which transports proteins among the
medial- and trans-Golgi compartments and is involved in signal
transduction and transporter activity. C16orf5  [Gen-
Bank:NM_013339] was confirmed in the initial set of samples,
and in an independent set it exhibited the same tendency in
relative expression level (1.4-fold change) but was eliminated
by the cut-off adoption criterion (fold change > 2). C16orf5
[GenBank:NM_013339] has an uncommonly high content of
proline residues (40% over 104 residues) at the amino-termi-
nus of the protein and is highly expressed in brain [43]. This
gene is also known as CDIP (cell death-inducing protein), a
potential apoptosis inducer that is associated with caspase-8
cleavage, implicating the extrinsic cell death pathway in apop-
tosis mediated by CDIP [44]. The over-expression of TXNL2
[GenBank: AL138831] in pure DCIS appears to be depend-
ent on the initial set of samples, because in the independent
group of samples we found the change in its expression to be
in the opposite direction (under-expression).
LOX  [GenBank:NM_002317] and SULF-1  [Gen-
Bank:NM_001128206] were over-expressed in the in situ
component of DCIS-IDC when compared with pure DCIS in
both initial and independent sample sets. The LOX  [Gen-
Bank:NM_002317] gene mediates metastasis of human
breast cancer cells in a mouse model [45] and regulates in
vitro  breast cancer cell migration and cell-matrix adhesion
through the regulation of Scr kinases and FAK [46], making it
a candidate for predicting progression of DCIS. Other recent
studies showed that LOX [GenBank:NM_002317] expression
correlates positively with tumor progression and co-localiza-
tion with hypoxic regions (defined by hypoxia inducible factor-
1α expression) in DCIS and IDC primary tumors [47]. The
gene  SULF-1  [GenBank:NM_001128206] modulates
heparin-binding growth factor signaling, and diminishes prolif-
eration and mitogenecity in vitro in head and neck squamous
carcinoma [48]. Evaluation of SULF-1  [Gen-
Bank:NM_001128206] expression levels in primary invasive
breast tumors by RNA in situ hybridization indicated that this
gene is down-regulated in the majority (60%) of samples, with
a predominant association with lobular histology [49], which is
a disagreement with our data. However, in human pancreatic
adenocarcinoma tumors this gene is upregulated, and it is
widely expressed in the human pancreatic adenocarcinoma
cell line [50]. Despite incomplete concordance among our
data and data from other groups for the SULF-1  [Gen-
Bank:NM_001128206] gene, over-expression in the in situ
component of DCIS-IDC and IDC samples was unequivocal.
Moreover,  SULF-1  [GenBank:NM_001128206] and LOX
[GenBank:NM_002317] exhibited statistically significant dif-
ferences when the samples were grouped based on invasive
behavior (non-neoplastic plus pure DCIS and in situ compo-
nent of DCIS-IDC plus IDC), suggesting their putative involve-
ment with the malignant transformation of DCIS.
The findings of the present study might have been influenced
by the small number of pure DCIS, which retain very specific
characteristic, such as high grade and HER2 positivity. Unfor-
tunately, this sample group, because of difficulty in obtaining
fresh tissue from this type of lesion, could not be evaluated as
an independent group. Therefore, the actual role of these can-
didate genes in the malignant process of DCIS requires further
investigation. Nevertheless, the evidence presented in this
study identifies these genes as potential candidates for pre-
dicting risk for progression of pure ductal carcinoma.
Conclusions
Our findings strongly suggest that the cells from DCIS with the
potential to become invasive exhibit modifications in the gen-
eral gene expression pattern before the morphological altera-
tion of lesion becomes visible. The SULF-1
[GenBank:NM_001128206] and LOX  [Gen-
Bank:NM_002317] genes are candidate molecular markers
that may be used to predict the risk for DCIS progression.
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